{"title":"Global Registries and Surveys Programme-Heart Failure (GRASP-HF): Rationale, study design and research implications.","authors":"Ovidiu Chioncel,Gianluigi Savarese,Cecile Laroche,Offer Amir,Mariya Tokmakova,Antonio Cannata,Loi Do Doan,Tarek Abdelhameed Nagib Ahmed Kafafy,Jan Krejci,Brenda Moura,Lars Lund,Marianna Adamo,Wendy Guillouche,Maurizio Volterani,Bernard Iung,Marco Metra, ","doi":"10.1002/ejhf.70065","DOIUrl":"https://doi.org/10.1002/ejhf.70065","url":null,"abstract":"Heart failure (HF) is characterized by increasing prevalence, high morbidity and mortality, poor quality of life, and substantial healthcare costs. Despite advancements in pharmacologic and device-based therapies, translating evidence from randomized controlled trials into clinical practice remains suboptimal. The Global Registries and Surveys Programme-Heart Failure (GRASP-HF) is a pan-European, snapshot, observational study, aiming at assessing the real-world implementation of evidence-based HF management. GRASP-HF captures both acute and chronic HF presentations to assess the adherence to the 2021 and 2023 European Society of Cardiology (ESC) HF Guidelines. It also serves as a platform for the accreditation of HF centres for the Improving Care through Accreditation and Recognition in Heart Failure (ICARe-HF) programme. This manuscript outlines the rationale, methodology, and design of GRASP-HF. Unlike previous registries, GRASP-HF ensures that all patients are consecutively enrolled over a pre-defined 2-month period, minimizing selection bias. GRASP-HF offers a real-time perspective on diagnostic strategies, use of guideline-recommended medical therapy and implementation of quality-of-care indicators. In addition, GRASP-HF addresses less explored domains by other registries, such as frailty, rare aetiologies (e.g. amyloidosis, genetic cardiomyopathies, Takotsubo syndrome), as well as non-fatal events during hospitalization and follow-up. GRASP-HF is also designed to inform ESC educational strategies and to benchmark progresses in HF care across European and non-European centres. In conjunction with ICARe-HF, annual repetition of GRASP-HF aims to facilitate continuous feedback between evidence, practice, and quality improvement. GRASP-HF will assist National Cardiac Societies in shaping national and institutional policies and will contribute with data-driven insights to future guideline development.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"108 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145339419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mark Luedde,Stefan Agewall,Giuseppe Ambrosio,Antoni Bayes-Genis,Claudio Borghi,Elisabetta Cerbai,Gheorghe A Dan,Heinz Drexel,Péter Ferdinandy,Erik Lerkevang Grove,Juan Carlos Kaski,Roland Klingenberg,Joao Morais,William Parker,Mark C Petrie,Bianca Rocca,Anne Grete Semb,Michele Senni,Christian Sohns,Patrick Sulzgruber,Juan Tamargo,Marco Metra,Michael Böhm,Dobromir Dobrev,Samuel Sossalla
{"title":"European Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to action.","authors":"Mark Luedde,Stefan Agewall,Giuseppe Ambrosio,Antoni Bayes-Genis,Claudio Borghi,Elisabetta Cerbai,Gheorghe A Dan,Heinz Drexel,Péter Ferdinandy,Erik Lerkevang Grove,Juan Carlos Kaski,Roland Klingenberg,Joao Morais,William Parker,Mark C Petrie,Bianca Rocca,Anne Grete Semb,Michele Senni,Christian Sohns,Patrick Sulzgruber,Juan Tamargo,Marco Metra,Michael Böhm,Dobromir Dobrev,Samuel Sossalla","doi":"10.1002/ejhf.70069","DOIUrl":"https://doi.org/10.1002/ejhf.70069","url":null,"abstract":"Heart failure (HF) and atrial fibrillation (AF) are major global health challenges with rising prevalence and significant morbidity, mortality, and healthcare burden. Despite advances in HF management, AF remains a critical comorbidity that worsens outcomes and requires ad hoc treatment strategies, increasing the risk of non-adherence and side effects. While rhythm control strategies in AF have gained attention for their prognostic benefits in HF, the pharmacological treatment of HF in patients with AF, including the benefit of rhythm versus rate control, remains underexplored. The relationship between HF and AF lacks sufficient evidence and targeted research to assess the optimal treatment strategies. This narrative review critically examines current HF pharmacotherapy in the context of AF, focusing on the four cornerstone treatments and modifiers of prognosis for HF with reduced ejection fraction: beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/sacubitril-valsartan, aldosterone antagonists, and sodium-glucose co-transporter 2 inhibitors. Although these therapies are well-established in HF patients, their efficacy in patients with concomitant AF requires further prospective investigation. The unique challenges posed by AF, including arrhythmia-induced remodelling and cardiomyopathy, necessitate a more individually tailored treatment. We also highlight critical knowledge gaps and the need for dedicated clinical trials specifically assessing HF therapies in AF subgroups, such as paroxysmal, long-standing persistent and permanent AF, and the benefit of heart rate and rhythm control strategies. The future of precision medicine in HF-AF management lies in bridging these evidence gaps through targeted research and interdisciplinary collaboration.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"17 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145338758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sam Straw,Pieter Martens,Nathan Mewton,Klaus K Witte,Wilfried Mullens
{"title":"The problem with hospitalization endpoints in heart failure trials.","authors":"Sam Straw,Pieter Martens,Nathan Mewton,Klaus K Witte,Wilfried Mullens","doi":"10.1002/ejhf.70070","DOIUrl":"https://doi.org/10.1002/ejhf.70070","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"72 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145331696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A U-shaped relationship between left ventricular ejection fraction and risk of worsening heart failure.","authors":"Hao-Chih Chang,Wei-Ming Huang,Liang-Yin Lin,Ching-Wei Lee,Chih-Hsueh Tseng,Wen-Chung Yu,Hao-Min Cheng,Chern-En Chiang,Chen-Huan Chen,Shih-Hsien Sung","doi":"10.1002/ejhf.70061","DOIUrl":"https://doi.org/10.1002/ejhf.70061","url":null,"abstract":"AIMSLeft ventricular ejection fraction (LVEF) is a key measure of cardiac function. While prior studies showed a U-shaped relationship between LVEF and mortality, its association with worsening heart failure (HF) remains unclear. We aimed to evaluate the association between the full spectrum of LVEF and the risk of worsening HF.METHODS AND RESULTSWe analysed data from 93 694 consecutive participants (median age 62 years [interquartile range: 50-76 years], 51.4% men) undergoing echocardiography at a tertiary medical centre. LVEF, measured by biplane Simpson's method, was categorized into 5% intervals from <20% to ≥70%. The primary outcome was a composite of all-cause mortality or worsening HF, while the secondary outcomes included all-cause mortality, cardiovascular death, and worsening HF. The primary outcome occurred in 32 398 (34.6%) participants over a median follow-up of 8.3 years. A U-shaped relationship between LVEF and the primary outcome was observed, with a nadir at 60-70% and an increased risk when LVEF was ≥70% [adjusted hazard ratio (aHR) 1.12; 95% confidence interval (CI) 1.06-1.18]. Similar patterns were observed for the secondary outcomes. Participants with LVEF ≥70% also had a higher risk of worsening HF (aHR 1.13, 95% CI 1.03-1.23). This U-shaped association was consistent across subgroups stratified by age, sex, hypertension, and diabetes, and was observed for both incident and recurrent HF events.CONCLUSIONSLeft ventricular ejection fraction demonstrated a U-shaped association with worsening HF, with the lowest risk at 60-70%. Supranormal LVEF (≥70%) identified a high-risk phenotype, underscoring the need for tailored management strategies for this subgroup.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"41 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145331749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cristina Madaudo, Amitai Segev, Emanuele Bobbio, Chiara Baggio, Jonathan Schütze, Piero Gentile, Marta Sanguineti, Luca Monzo, Matteo Schettino, Emma Ferone, Ahmed Elsanhoury, Anan Younis, Matteo Palazzini, Adriana Ferroni, Valentina Giani, Matthew Sadler, Mohammad Albarjas, Leonardo Calò, Christian Lars Polte, Andrea Garascia, Stefano Figliozzi, Paul A. Scott, Ajay M. Shah, Alfredo Ruggero Galassi, Mauro Giacca, Gianfranco Sinagra, Entela Bollano, Theresa McDonagh, Carsten Tschöpe, Giuseppina Novo, Enrico Ammirati, Roy Beigel, Christoph Gräni, Marco Merlo, Pietro Ameri, Antonio Cannata, Daniel I. Bromage
{"title":"Neutrophil-to-lymphocyte ratio for risk stratification in acute myocarditis across the left ventricular ejection fraction spectrum","authors":"Cristina Madaudo, Amitai Segev, Emanuele Bobbio, Chiara Baggio, Jonathan Schütze, Piero Gentile, Marta Sanguineti, Luca Monzo, Matteo Schettino, Emma Ferone, Ahmed Elsanhoury, Anan Younis, Matteo Palazzini, Adriana Ferroni, Valentina Giani, Matthew Sadler, Mohammad Albarjas, Leonardo Calò, Christian Lars Polte, Andrea Garascia, Stefano Figliozzi, Paul A. Scott, Ajay M. Shah, Alfredo Ruggero Galassi, Mauro Giacca, Gianfranco Sinagra, Entela Bollano, Theresa McDonagh, Carsten Tschöpe, Giuseppina Novo, Enrico Ammirati, Roy Beigel, Christoph Gräni, Marco Merlo, Pietro Ameri, Antonio Cannata, Daniel I. Bromage","doi":"10.1002/ejhf.70072","DOIUrl":"https://doi.org/10.1002/ejhf.70072","url":null,"abstract":"Acute myocarditis (AM) is a heterogeneous clinical condition. Several classification models have been proposed to predict adverse clinical outcomes, but risk stratification remains challenging, particularly for patients presenting with preserved left ventricular ejection fraction (LVEF). Neutrophil-to-lymphocyte ratio (NLR) is a useful tool for risk stratification in patients with AM. This study aimed to compare the predictive accuracy of available risk stratification models, including NLR, for identifying patients with AM at increased risk of adverse events.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"20 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145296169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lucia Venneri, Alberto Aimo, Aldostefano Porcari, Irem Sezer, Adam Ioannou, Awais Sheikh, Josephine Mansell, Yousuf Razvi, Surabhi Bhaskar Iyer, Ana Martinez-Naharro, Francesco Bandera, Sze Chi Lim, Matthew Frost, Justin Ezekowitz, Carolyn S.P. Lam, William Moody, Carol Whelan, Helen Lachmann, Ashutosh Wechelakar, Michele Emdin, Philip N. Hawkins, Scott David Solomon, Julian D. Gillmore, Marianna Fontana
{"title":"Artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis","authors":"Lucia Venneri, Alberto Aimo, Aldostefano Porcari, Irem Sezer, Adam Ioannou, Awais Sheikh, Josephine Mansell, Yousuf Razvi, Surabhi Bhaskar Iyer, Ana Martinez-Naharro, Francesco Bandera, Sze Chi Lim, Matthew Frost, Justin Ezekowitz, Carolyn S.P. Lam, William Moody, Carol Whelan, Helen Lachmann, Ashutosh Wechelakar, Michele Emdin, Philip N. Hawkins, Scott David Solomon, Julian D. Gillmore, Marianna Fontana","doi":"10.1002/ejhf.70073","DOIUrl":"https://doi.org/10.1002/ejhf.70073","url":null,"abstract":"In transthyretin amyloid cardiomyopathy (ATTR-CM), reduced stroke volume (SV) portends a poor prognosis. Artificial intelligence (AI) enables rapid, standardized assessment of left ventricular outflow tract velocity-time integral (LVOT-VTI), which is a reliable surrogate for SV. We investigated longitudinal changes in AI-derived LVOT-VTI as outcome predictors in ATTR-CM.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"32 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145296167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Luis Eduardo Echeverria, Caroline Demacq, Claudio Gimpelewicz, John J V McMurray, Renato Delascio Lopes
{"title":"Reply to the letter regarding the article 'Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial'.","authors":"Luis Eduardo Echeverria, Caroline Demacq, Claudio Gimpelewicz, John J V McMurray, Renato Delascio Lopes","doi":"10.1002/ejhf.70062","DOIUrl":"https://doi.org/10.1002/ejhf.70062","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.8,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145285122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Letter regarding the article ‘Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE‐HF trial’","authors":"Dan Xiong","doi":"10.1002/ejhf.70058","DOIUrl":"https://doi.org/10.1002/ejhf.70058","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"94 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145282739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alberto Aimo,Laurens F Tops,Stamatis Adamopoulos,Michael Bonios,Ahmet Çelik,Ovidiu Chioncel,Maja Cikes,Maria G Crespo-Leiro,Kevin Damman,Concetta Di Nora,Julien Dreyfus,Finn Gustafsson,Shahrukh Hashmani,Marco Masetti,Ify Mordi,Sanem Nalbantgil,Linda W van Laake,Ralph Stephan von Bardeleben,Marco Metra,Tuvia Ben Gal,Brenda Moura
{"title":"Multimodality imaging in advanced heart failure. A clinical consensus statement of the Heart Failure Association of the ESC. Part 1: Multimodality imaging for the evaluation of patients with advanced heart failure.","authors":"Alberto Aimo,Laurens F Tops,Stamatis Adamopoulos,Michael Bonios,Ahmet Çelik,Ovidiu Chioncel,Maja Cikes,Maria G Crespo-Leiro,Kevin Damman,Concetta Di Nora,Julien Dreyfus,Finn Gustafsson,Shahrukh Hashmani,Marco Masetti,Ify Mordi,Sanem Nalbantgil,Linda W van Laake,Ralph Stephan von Bardeleben,Marco Metra,Tuvia Ben Gal,Brenda Moura","doi":"10.1002/ejhf.3762","DOIUrl":"https://doi.org/10.1002/ejhf.3762","url":null,"abstract":"Heart failure (HF) represents a significant global health burden, with approximately 10% of patients progressing to advanced stages characterized by severe symptoms and recurrent hospitalizations despite conventional treatments such as guideline-directed medical therapy, devices, and surgery. This clinical consensus statement from the Heart Failure Association of the European Society of Cardiology discusses the applications of imaging modalities in patients with advanced HF. Transthoracic echocardiography remains the cornerstone for initial diagnosis and monitoring, providing critical insights into cardiac volumes, function, and valvular integrity, as well as congestion status. Transoesophageal echocardiography offers detailed evaluations of valve pathology, essential for surgical or transcatheter planning. Cardiovascular magnetic resonance provides comprehensive assessments of biventricular size and function, tissue characterization, and flow dynamics, proving particularly useful for diagnosing specific HF aetiologies. Computed tomography offers valuable insights into pulmonary artery diameter, right ventricular volume, and valvular anatomy, which are crucial for guiding percutaneous procedures. Nuclear imaging techniques allow assessing viability and diagnosing non-ischaemic HF conditions, guiding revascularization decisions. Advanced imaging techniques have expanded the understanding and management of right ventricular dysfunction. The integration of these advanced imaging modalities enhances diagnostic accuracy, risk stratification, and therapeutic decision-making, ultimately improving the prognosis and quality of life for patients with advanced HF. This clinical consensus statement highlights the critical role of various imaging modalities in managing patients with advanced HF, excluding those needing mechanical circulatory support or heart transplantation, emphasizing the multifaceted approach required for effective management.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"1 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145283948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laurens F Tops,Alberto Aimo,Stamatis Adamopoulos,Michael Bonios,Ahmet Çelik,Ovidiu Chioncel,Maja Cikes,Maria G Crespo-Leiro,Kevin Damman,Concetta Di Nora,Julien Dreyfus,Finn Gustafsson,Shahrukh Hashmani,Marco Masetti,Ify Mordi,Sanem Nalbantgil,Linda W van Laake,Ralph Stephan von Bardeleben,Marco Metra,Brenda Moura,Tuvia Ben Gal
{"title":"Multimodality imaging in advanced heart failure. A clinical consensus statement of the Heart Failure Association of the ESC. Part 2: Mechanical circulatory support and heart transplantation.","authors":"Laurens F Tops,Alberto Aimo,Stamatis Adamopoulos,Michael Bonios,Ahmet Çelik,Ovidiu Chioncel,Maja Cikes,Maria G Crespo-Leiro,Kevin Damman,Concetta Di Nora,Julien Dreyfus,Finn Gustafsson,Shahrukh Hashmani,Marco Masetti,Ify Mordi,Sanem Nalbantgil,Linda W van Laake,Ralph Stephan von Bardeleben,Marco Metra,Brenda Moura,Tuvia Ben Gal","doi":"10.1002/ejhf.70018","DOIUrl":"https://doi.org/10.1002/ejhf.70018","url":null,"abstract":"This clinical consensus statement outlines the vital role of multimodality imaging in managing patients with advanced heart failure (HF), particularly those receiving mechanical circulatory support (MCS) and heart transplantation (HT). For both temporary and durable MCS, multimodality imaging, primarily echocardiography, is crucial for selecting candidates, ensuring proper device placement, and monitoring in the post-implantation period. Preoperatively, it helps to identify HF phenotypes, assess ventricular functions, detect intracardiac thrombi, and evaluate valvular conditions. Key measurements include ventricular size, ejection fraction, and cardiac output. Intraoperative imaging ensures optimal device placement and complication detection. Post-implantation echocardiography gives an impression of the interplay between heart and MCS, detects early complications, and evaluates ventricular unloading and right ventricular function. Serial imaging evaluations are essential for the management of the patient and the device and for diagnosing and treatment of complications. In temporary MCS, imaging is vital in the weaning process. Imaging is crucial across various post-transplant phases, from early postoperative monitoring to long-term follow-up. Echocardiography is the first-line technique. Cardiovascular magnetic resonance provides detailed evaluation of cardiac structure and function, offering insights into fibrosis, oedema, and myocardial perfusion. Coronary computed tomography angiography and positron emission tomography are possible alternatives for assessing coronary allograft vasculopathy. Overall, multimodality imaging is pivotal for comprehensive management of patients potentially eligible to or undergoing MCS or HT, enhancing diagnostic accuracy and guiding therapeutic decisions.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"213 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145283954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}